Increasing Permeability Segment to dominate Middle East & Africa Blood Brain Barrier Technologies Market during 2021–2028
According to The Insight Partners market research study on “Middle East & Africa Blood Brain Barrier Technologies Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Technology and Application,” is expected to reach US$ 196.72 million by 2028 from US$ 43.51 million in 2021. The market is estimated to grow at a CAGR of 24.1% from 2021 to 2028. The report provides trends prevailing in the Middle East & Africa blood brain barrier technologies market along with the drivers and restraints pertaining to the market growth. Higher number of product approvals and launches, elevating demand nanoparticles for brain drug delivery, and scaling geriatric population and rising prevalence of age-associated neurological disorders are the major factor driving the growth of the Middle East & Africa blood brain barrier technologies market. However, hurdles in brain medication delivery hinders the growth of Middle East & Africa blood brain barrier technologies market.
Countries such as UAE, and Saudi Arabia have also registered a significant number of positive patients. The COVID-19 pandemic has become the most significant challenge in the region. This challenge will be especially frightening for the region’s fragile and conflict-torn states—such as Iraq (1,963,264), Sudan (38,000), Iran (5,378,408), Israel (1,202,212) and Yemen (8,527) as it will lead to reduce imports due to disruptions in global trade, which further increases the shortages of medical supplies and other goods, resulting in a considerable price increase. The blood brain barrier technologies market in this pandemic is on rising, due to more of research about relation of blood brain barrier technologies with COVID-19 infection and its effect on the human body. Thus, pandemic has a positive impact on blood brain barrier technologies market.
The Middle East & Africa blood brain barrier technologies market is segmented on the basis of technology, application, and country. Based on technology, the blood brain barrier technologies market is segmented into bispecific antibody RMT approach, trojan horse approach, increasing permeability, passive diffusion, and other non-invasive BBB technologies. In 2021, increasing permeability segment held the largest share in the market, and it is also expected to be the fastest growing segment during the forecast period. On the basis of application, the blood brain barrier technologies market is segmented into alzheimer’s disease, epilepsy, parkinson’s disease, multiple sclerosis, hunter’s syndrome, brain cancer, and others. In 2021, parkinson’s disease segment held the largest share in the market, and epilepsy is expected to be the fastest growing segment during the forecast period. Similarly, Based on country the market is segmented into Saudi Arabia, South Africa, the UAE, and Rest of MEA. In 2021, Saudi Arabia held the largest share in the market, and the UAE is expected to be the fastest growing country during the forecast period.
Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Bristol-Myers Squibb Company; Pfizer, Inc.; and Johnson & Johnson Services, Inc. are among the leading companies in the Middle East & Africa blood brain barrier technologies market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com